Latest data shows the largest indicative borrow rate increases among liquid option names include: Galectin Therapeutics (GALT) 85.37% +13.41, ...

Galectin Therapeutics Inc. Common Stock (GALT) stock saw a decline, ending the day at $1.04 which represents a decrease of $-0.96 or -48.00% from the prior close of $2. The stock opened at $1.18 and ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Get ahead of the market by subscribing to Seeking Alpha's Wall Street Week Ahead, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to ...

Galectin Therapeutics shares fell after it said the endpoint of a liver-disease treatment trial didn't meet statistical significance. The stock lost more than half its value, falling to about 91 cents ...

Shares of Personalis, Inc. PSNL got a boost, surging 25% to $6.55 after the company and Moderna recently announced a ...

Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce ...

Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint ...

Galectin Therapeutics' NAVIGATE trial shows belapectin reduces varices in MASH cirrhosis, but falls short of statistical targets; full data due in early 2025.

Galectin Therapeutics (GALT) announced results from its global clinical trial NAVIGATE evaluating belapectin in patients with Metabolic ...

The renewed agreement marks a key milestone as Gray Media prepares to adopt Comscore's cross-platform measurement solution, Comscore Campaign Ratings (CCR), starting in 2025. CCR will enable Gray to ...

Galectin Therapeutics (GALT) stock drops 25% as NAVIGATE trial for belapectin in liver disorder MASH fails to meet main goal.